ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jaybe	5/18/2016 8:51:13 PM
	of 4474

A few highlights from the pona abstracts... abstracts.asco.org Conclusions: Deep, early reductions in BCR-ABL1 transcripts were positively associated with LT survival in this refractory population. These data demonstrate the prognostic value of achieving early landmark cytogenetic and molecular responses with PON in heavily pretreated pts. http://abstracts.asco.org/176/AbstView_176_164576.html Conclusions: The clinical outcome of HCVAD + ponatinib appears superior to that of HCVAD + dasatinib. Prospective confirmation of these results is warranted. http://abstracts.asco.org/176/AbstView_176_163683.html Conclusions: After 4 yrs,heavilypretreated pts continue to show deep and lasting responses on ponatinib, and ~2 yrs post recommended dose reductions, maintenance of response is high, and the incidence of newly occurring AOEs has decreased.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next